Garden Stage Regains Nasdaq Compliance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy GSIW?
Garden Stage announced that it received a notification letter from the Nasdaq notifying the company that it has regained compliance with Nasdaq's minimum bid price requirement and that the matter is now closed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GSIW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GSIW
About GSIW
Garden Stage Ltd is a holding company principally engaged in the provision of financial services. The Company is principally engaged in the provision of securities dealing and brokerage services, securities underwriting and placing services, asset management services as well as others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Garden Stage Regains Nasdaq Compliance
- Compliance Restoration: Garden Stage confirmed its compliance with Nasdaq's minimum bid price requirements on March 20, 2026, effectively resolving compliance issues that began in September 2025, demonstrating effective stock price management by the company.
- Share Consolidation: To address the sub-$1 share price issue, the company executed a 200-for-1 share consolidation on March 6, 2026, successfully elevating its stock price to compliant levels and boosting investor confidence.
- Extended Compliance Deadline: Nasdaq provided Garden Stage with compliance deadlines, including an extension through September 1, 2026, indicating regulatory support and attention towards the company.
- Stock Price Performance: Following the consolidation, Garden Stage maintained a share price above $1 from March 6 to March 19, 2026, ensuring its continued listing eligibility on Nasdaq.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points
- Dow Jones Performance: The Dow Jones index gained over 100 points on Wednesday, rising 0.25% to close at 48,622.74, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.69% to 22,672.12, while the S&P 500 rose 0.37% to 6,841.53, reflecting strong performances in the technology and consumer sectors.
- Abercrombie & Fitch Earnings: The company reported Q4 earnings of $3.68 per share, beating analyst expectations of $3.57, yet its stock fell around 5%, indicating market concerns about future performance.
- Private Sector Job Data: U.S. private businesses added 63,000 jobs in February, significantly exceeding market estimates of 50,000, suggesting a robust economic recovery that could positively impact the stock market.
See More
Garden Stage Limited Announces 200-for-1 Share Consolidation
- Share Consolidation Plan: Garden Stage Limited announced a 200-for-1 share consolidation effective March 6 to comply with Nasdaq Marketplace Rule 5550(a)(2), aiming to enhance investor confidence and maintain its listing status.
- Trading Symbol Unchanged: Post-consolidation, the company's Class A shares will continue trading on the Nasdaq Capital Market under the symbol 'GSIW', but with a new CUSIP number G3730L131, ensuring market liquidity and transparency.
- Change in Share Count: Before the consolidation, the company had 282,485,623 Class A shares outstanding, which is expected to reduce to approximately 1,412,428 shares post-consolidation, while Class B shares will remain unchanged at 9,250,000, reflecting the company's efforts to optimize its capital structure.
- Market Reaction: Following the consolidation announcement, GSIW's stock price fell 36.88% in pre-market trading to $0.0568, indicating market caution regarding the company's future prospects, which may impact investor confidence and subsequent financing capabilities.
See More
GARDEN STAGE LIMITED DECLARES 200 FOR 1 CONSOLIDATION OF CLASS A SHARES
- Company Announcement: Gardens Stage Limited has announced a consolidation of Class A shares.
- Share Conversion Rate: The consolidation will occur at a rate of 200 for 1 share.
See More
Garden Stage Regains Nasdaq Compliance
- Compliance Restoration: Garden Stage confirmed its compliance with Nasdaq's minimum bid price requirements on March 20, 2026, effectively resolving compliance issues that began in September 2025, demonstrating effective stock price management by the company.
- Share Consolidation: To address the sub-$1 share price issue, the company executed a 200-for-1 share consolidation on March 6, 2026, successfully elevating its stock price to compliant levels and boosting investor confidence.
- Extended Compliance Deadline: Nasdaq provided Garden Stage with compliance deadlines, including an extension through September 1, 2026, indicating regulatory support and attention towards the company.
- Stock Price Performance: Following the consolidation, Garden Stage maintained a share price above $1 from March 6 to March 19, 2026, ensuring its continued listing eligibility on Nasdaq.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
- Market Decline: U.S. stocks fell broadly on Monday, with the Dow Jones index dropping around 650 points, indicating investor concerns about economic outlook which may impact consumer spending and overall market confidence.
- Relmada Stock Surge: Shares of Relmada Therapeutics Inc. soared 40.8% to $6.27 during Monday's session, driven by the release of promising interim data from its Phase 2 trial of NDV-01 for treating non-muscle invasive bladder cancer.
- Clinical Trial Results: The 12-month interim data revealed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population, providing strong support for Relmada's treatment approach and potentially enhancing market acceptance.
- Positive Market Reaction: The favorable feedback from clinical data has led to optimistic investor sentiment regarding Relmada's future prospects, not only boosting the company's stock price but also likely attracting more investor interest in its ongoing research and development efforts.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 100 Points
- Dow Jones Performance: The Dow Jones index gained over 100 points on Wednesday, rising 0.25% to close at 48,622.74, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ climbed 0.69% to 22,672.12, while the S&P 500 rose 0.37% to 6,841.53, reflecting strong performances in the technology and consumer sectors.
- Abercrombie & Fitch Earnings: The company reported Q4 earnings of $3.68 per share, beating analyst expectations of $3.57, yet its stock fell around 5%, indicating market concerns about future performance.
- Private Sector Job Data: U.S. private businesses added 63,000 jobs in February, significantly exceeding market estimates of 50,000, suggesting a robust economic recovery that could positively impact the stock market.
See More
Garden Stage Limited Announces 200-for-1 Share Consolidation
- Share Consolidation Plan: Garden Stage Limited announced a 200-for-1 share consolidation effective March 6 to comply with Nasdaq Marketplace Rule 5550(a)(2), aiming to enhance investor confidence and maintain its listing status.
- Trading Symbol Unchanged: Post-consolidation, the company's Class A shares will continue trading on the Nasdaq Capital Market under the symbol 'GSIW', but with a new CUSIP number G3730L131, ensuring market liquidity and transparency.
- Change in Share Count: Before the consolidation, the company had 282,485,623 Class A shares outstanding, which is expected to reduce to approximately 1,412,428 shares post-consolidation, while Class B shares will remain unchanged at 9,250,000, reflecting the company's efforts to optimize its capital structure.
- Market Reaction: Following the consolidation announcement, GSIW's stock price fell 36.88% in pre-market trading to $0.0568, indicating market caution regarding the company's future prospects, which may impact investor confidence and subsequent financing capabilities.
See More
GARDEN STAGE LIMITED DECLARES 200 FOR 1 CONSOLIDATION OF CLASS A SHARES
- Company Announcement: Gardens Stage Limited has announced a consolidation of Class A shares.
- Share Conversion Rate: The consolidation will occur at a rate of 200 for 1 share.
See More
